Skip to main content

Antimicrobial Susceptibility Testing Market by Product, Type, Application, Method, End-user - Global Forecasts to 2025 - ResearchAndMarkets.com

The "Antimicrobial Susceptibility Testing Market by Product (Manual, Automated Susceptibility Testing System), Type (Antibacterial, Antifungal), Application (Clinical Diagnostics), Method (ETEST, Disk Diffusion), End-User - Global Forecasts to 2025" report has been added to ResearchAndMarkets.com's offering.

The antimicrobial susceptibility testing market is projected to reach USD 4.2 billion by 2025 from USD 3.2 billion in 2020, at a CAGR of 5.5% during the forecast period.

Growth of the market is mainly attributed to the technological advancements; increasing incidences of infectious diseases, and growing public and private investments, funding, and grants are driving the global antimicrobial susceptibility testing market. However, complex regulatory frameworks that delay the approval of new microbial susceptibility tests is expected to challenge market growth to a certain extent.

In terms of products, automated laboratory instruments segment to register significant growth during the forecast period.

Based on the product, the antimicrobial susceptibility testing market is segmented into automated laboratory instruments, manual antimicrobial susceptibility testing products, culture and growth media, and consumables. Significant growth of the segment is attributed to the ongoing trend of laboratory automation among clinical laboratories, advantages offered by automated AST instruments over manual susceptibility instruments, and technological advancements in the market. Automated instruments offer a wide range of advantages over manual susceptibility testing products, such as reduced labor cost, shortened incubation time, and large-volume sample handling. These advantages offered by the automated systems have led to the growth of this segment.

Clinical diagnostics application segment is expected to witness the highest growth in the AST market, during the forecast period.

Based on application, the antimicrobial susceptibility testing market has been segmented into the antimicrobial susceptibility testing market is segmented into clinical diagnostics, drug discovery and development, epidemiology, and other applications. The growth in this market is attributed to the rising prevalence of infectious diseases, increasing incidence of HAIs, large target patient population base (especially in emerging countries), the growing procedural volume of clinical diagnostic tests, rising emphasis on effective and early disease diagnosis across major markets, and the introduction of various technologically advanced susceptibility testing products.

Diagnostic laboratories and hospitals segment is expected to account for the largest share of the AST market, by the end user

On the basis of end-users, the antimicrobial susceptibility testing market has been segmented into diagnostic laboratories and hospitals, pharmaceutical and biotechnology companies, contract research organizations (CROs), and research and academic institutes. The growth of this segment is attributed to the significant number of antibacterial, antiparasitic, and antifungal tests procedures performed in diagnostic laboratories and hospitals; and the growing number of hospitals across major markets. Moreover, a growing trend towards the utilization of rapid AST platforms and improving healthcare expenditure in emerging markets will further boost the growth of this segment in the coming years.

Asia Pacific market is expected to grow at the highest CAGR during the forecast period.

The Asia Pacific market is estimated to grow at the highest CAGR during the forecast period majorly due to the heavy burden of infectious diseases, rising healthcare expenditure, and increasing research into AST. Apart from this, the rising number of biotechnology and pharmaceutical companies in the APAC region is expected to propel the market for antimicrobial susceptibility testing.

Market Dynamics

Drivers

  • Rising Incidence of Infectious Diseases Coupled with Epidemic & Pandemic Events
  • Increasing Funding, Research Grants, and Public-Private Investments in the Market
  • Technological Advancements
  • Growing Government Initiatives to Detect and Control Antimicrobial-Resistant Species
  • Emergence of Multidrug-Resistance Due to Drug Abuse

Restraints

  • High Cost of Automated Id/AST Systems

Opportunities

  • Emerging Markets
  • Awareness Initiatives for Antimicrobial Resistance and Its Control

Challenges

  • Complex Regulatory Frameworks That Delay Antimicrobial Testing Approvals

Companies Mentioned

  • Accelerate Diagnostics, Inc.
  • Alifax S.R.L.
  • Becton, Dickinson and Company
  • Bioanalyse
  • Biomerieux Sa
  • Bio-Rad Laboratories, Inc.
  • Bruker
  • Condalab
  • Creative Diagnostics
  • Danaher Corporation
  • Elitechgroup
  • Genefluidics, Inc.
  • Himedia Laboratories
  • Liofilchem S.R.L.
  • Mast Group Ltd.
  • Merck Kgaa
  • Roche Diagnostics
  • Synbiosis
  • Thermo Fisher Scientific
  • Zhuhai Dl Biotech Co. Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/oxnxw0

Contacts:

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.